CFTR and cystic fibrosis: In a recent phase 2 clinical trial in CF patients carrying the gating mutation G551D, the CFTR potentiator VX-770 [11] induced CFTR-mediated Cl− secretion in nasal epithelia in vivo to levels of ∼20% of normal [12], [13].